Literature DB >> 22726954

Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

Kiyoshi Hirahara1, Kamran Ghoreschi, Xiang-Ping Yang, Hayato Takahashi, Arian Laurence, Golnaz Vahedi, Giuseppe Sciumè, Aisling O'Hara Hall, Christopher D Dupont, Loise M Francisco, Qian Chen, Masao Tanaka, Yuka Kanno, Hong-Wei Sun, Arlene H Sharpe, Christopher A Hunter, John J O'Shea.   

Abstract

Interleukin-27 (IL-27) is a key immunosuppressive cytokine that counters T helper 17 (Th17) cell-mediated pathology. To identify mechanisms by which IL-27 might exert its immunosuppressive effect, we analyzed genes in T cells rapidly induced by IL-27. We found that IL-27 priming of naive T cells upregulated expression of programmed death ligand 1 (PD-L1) in a signal transducer and activator of transcription 1 (STAT1)-dependent manner. When cocultured with naive CD4(+) T cells, IL-27-primed T cells inhibited the differentiation of Th17 cells in trans through a PD-1-PD-L1 interaction. In vivo, coadministration of naive TCR transgenic T cells (2D2 T cells) with IL-27-primed T cells expressing PD-L1 inhibited the development of Th17 cells and protected from severe autoimmune encephalomyelitis. Thus, these data identify a suppressive activity of IL-27, by which CD4(+) T cells can restrict differentiation of Th17 cells in trans.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726954      PMCID: PMC3785111          DOI: 10.1016/j.immuni.2012.03.024

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

1.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 2.  Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Authors:  Lieping Chen
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

3.  Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock.

Authors:  Marina Karaghiosoff; Ralf Steinborn; Pavel Kovarik; Gernot Kriegshäuser; Manuela Baccarini; Birgit Donabauer; Ursula Reichart; Thomas Kolbe; Christian Bogdan; Tomas Leanderson; David Levy; Thomas Decker; Mathias Müller
Journal:  Nat Immunol       Date:  2003-04-07       Impact factor: 25.606

4.  Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.

Authors:  Masako Chiyo; Osamu Shimozato; Ling Yu; Kiyoko Kawamura; Toshihiko Iizasa; Takehiko Fujisawa; Masatoshi Tagawa
Journal:  Int J Cancer       Date:  2005-06-20       Impact factor: 7.396

5.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

Authors:  Yvette E Latchman; Spencer C Liang; Yin Wu; Tatyana Chernova; Raymond A Sobel; Martina Klemm; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.

Authors:  Bettina Schreiner; Meike Mitsdoerffer; Bernd C Kieseier; Lieping Chen; Hans-Peter Hartung; Michael Weller; Heinz Wiendl
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

7.  Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.

Authors:  J E Durbin; R Hackenmiller; M C Simon; D E Levy
Journal:  Cell       Date:  1996-02-09       Impact factor: 41.582

8.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection.

Authors:  Alejandro Villarino; Linda Hibbert; Linda Lieberman; Emma Wilson; Tak Mak; Hiroki Yoshida; Robert A Kastelein; Christiaan Saris; Christopher A Hunter
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

9.  The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis.

Authors:  Bernhard Greve; Lalitha Vijayakrishnan; Aarup Kubal; Raymond A Sobel; Laurence B Peterson; Linda S Wicker; Vijay K Kuchroo
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

10.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.

Authors:  Claire L Langrish; Yi Chen; Wendy M Blumenschein; Jeanine Mattson; Beth Basham; Jonathan D Sedgwick; Terrill McClanahan; Robert A Kastelein; Daniel J Cua
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

View more
  121 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

Review 2.  CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm.

Authors:  Kiyoshi Hirahara; Toshinori Nakayama
Journal:  Int Immunol       Date:  2016-02-12       Impact factor: 4.823

3.  Loss of IL-27Rα Results in Enhanced Tubulointerstitial Fibrosis Associated with Elevated Th17 Responses.

Authors:  Gaia M Coppock; Lillian R Aronson; Jihwan Park; Chengxiang Qiu; Jeongho Park; Jonathan H DeLong; Enrico Radaelli; Katalin Suszták; Christopher A Hunter
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

Review 4.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

5.  ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Authors:  Frank P Vendetti; Pooja Karukonda; David A Clump; Troy Teo; Ronald Lalonde; Katriana Nugent; Matthew Ballew; Brian F Kiesel; Jan H Beumer; Saumendra N Sarkar; Thomas P Conrads; Mark J O'Connor; Robert L Ferris; Phuoc T Tran; Greg M Delgoffe; Christopher J Bakkenist
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

6.  Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.

Authors:  Stephan Wilmes; Polly-Anne Jeffrey; Jonathan Martinez-Fabregas; Maximillian Hafer; Paul K Fyfe; Elizabeth Pohler; Silvia Gaggero; Martín López-García; Grant Lythe; Charles Taylor; Thomas Guerrier; David Launay; Suman Mitra; Jacob Piehler; Carmen Molina-París; Ignacio Moraga
Journal:  Elife       Date:  2021-04-19       Impact factor: 8.140

7.  Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell-mediated colitis and induces multiple inhibitory pathways in T cells.

Authors:  Xiaotong Zhu; Zhihao Liu; Jin-Qing Liu; Jianmin Zhu; Jianchao Zhang; Jonathan P Davis; Jianhong Chu; Jianhua Yu; Jie Zhou; Ming-Song Li; Xue-Feng Bai
Journal:  J Leukoc Biol       Date:  2016-04-22       Impact factor: 4.962

8.  Histone deacetylase sirtuin 1 deacetylates IRF1 protein and programs dendritic cells to control Th17 protein differentiation during autoimmune inflammation.

Authors:  Heeyoung Yang; Sang-Myeong Lee; Beixue Gao; Jinping Zhang; Deyu Fang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.